1887
Volume 2022 Number 3
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

The production of a successful vaccine has become a global dream since the declaration of coronavirus disease 2019 (COVID-19) as a global pandemic by the World Health Organization. However, doubts abound about vaccine safety. In this study, we aimed to estimate and compare the prevalence of adverse effects in Iraqi adults from the COVID-19 vaccines used in Iraq. The study was a retrospective, cross-sectional study conducted in August 2021. An online-based questionnaire was applied randomly and distributed to individuals ( ≥ 18 years). : Among the 1000 vaccinated participants from different regions in Iraq, 66.0% were from middle Euphrates, 61.3% were women, and 62.2% were in their third to fifth decade of life. Approximately, 68.4% of the participants received Pfizer vaccine, and 42.5% had a previous history of COVID-19 infection Figure 1. Most of the participants (84.1%) suffered general adverse effects after vaccination, including (in sequence of appearance) fatigue, fever, headache, injection site signs, and axillary pain. Most studied factors have no significant correlation with post-vaccine adverse effects ( ≤  0.05) such as age, sex, history of COVID-19 infection, and chronic disease. There was a significant correlation between adverse effects from the vaccine dose and age of recipients. Those with a history of comorbidities had a two-fold risk of developing adverse effects.Figure 1.  Prevalence of general adverse effects in the participants after vaccination with three types of COVID-19 vaccines (N = 1000).

Fatigue, fever, headache, injection site signs, and axillary pain were the most registered adverse effects, which were mostly mild to moderate. All the vaccines revealed an encouraging safety profile. Younger age, second vaccine dose, and presence of comorbidities were considered minor risk factors for more adverse effects.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2022.ismc.6
2022-06-17
2022-08-10
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2022/3/jemtac.2022.ismc.6.html?itemId=/content/journals/10.5339/jemtac.2022.ismc.6&mimeType=html&fmt=ahah

References

  1. Al-Hindy HA-AM, Mazin J, Hashim HO. BCG Vaccine in preventing COVID-19 epidemic had to be reviewed: correlation does not imply causation. Australian Journal of Basic and Applied Sciences. 2020; 14:(11):58–63.
    [Google Scholar]
  2. Al Sa'ady AT, Samah AKAJ, Hussein FH. COVID-19 the problematically confusing virus. Open Access Journal of Toxicology. 2020; 4:(3):0095-0096.
    [Google Scholar]
  3. Hashim HO, Mohammed MK, Mousa MJ, Abdulameer HH, Alhassnawi ATS, Hassan SA, Al-Shuhaib MBS. Infection with different strains of SARS-CoV-2 in patients with COVID-19. Archives of Biological Sciences. 2020; 72:(4):575–85.
    [Google Scholar]
  4. Luyten JB, Bruneel L, van Hoek AJ. Assessing vaccine hesitancy in the UK population using a generalized vaccine hesitancy survey instrument. Vaccine. 2019; 37:(18):2494–501.
    [Google Scholar]
  5. Hussein FH, Al Sa'ady AT, Khadum SA. COVID-19, prophylaxis and treatment. 1st ed. Dar Al-Waddah For Publishing & Distribution. 2021.
    [Google Scholar]
  6. Centers for Disease Control and Prevention. Possible side effects after getting a COVID-19 vaccine. [Internet]. CDC; 2021 [accessed June 25, 2021]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html..
    [Google Scholar]
  7. Centers for Disease Control and Prevention. What you should know about the possibility of COVID-19 illness after vaccination. [Internet]. CDC; 2021 [accessed April 27, 2021]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html.
    [Google Scholar]
  8. Vogel TP, Top KA, Karatzios C, Hilmers DC, Tapia LI, Moceri P, et al. Multisystem inflammatory syndrome in children and adults (MIS-C/A): case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2021; 39:(22):3037–49.
    [Google Scholar]
  9. Andrzejczak-Grządko S, Czudy Z, Donderska M. Side effects after COVID-19 vaccinations among residents of Poland. European Review for Medical and Pharmacological Sciences. 2021; 25:(12):4418–21.
    [Google Scholar]
  10. World Health Organization. Side effects of COVID-19 Vaccines, [Internet]. WHO; 2021. Available from: https://www.who.int/news-room/feature-stories/detail/side-effects-of-covid-19-vaccines.
    [Google Scholar]
  11. Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. International Journal of Infectious Diseases. 2021;:106:376–81.
    [Google Scholar]
  12. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases. 2021; 21:(7):939–49.
    [Google Scholar]
  13. Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. Journal of Clinical Medicine. 2021; 10:(7):1428.
    [Google Scholar]
  14. El-Shitany NA, Harakeh S, Badr-Eldin SM, Bagher AM, Eid B, Almukadi H, et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study. International Journal of General Medicine. 2021:(14):1389–401.
    [Google Scholar]
  15. Hatmal MmM, Al-Hatamleh MA, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, et al., Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines. 2021; 9:(6):556.
    [Google Scholar]
  16. Jayadevan R, Shenoy R, Anithadevi TS. Survey of symptoms following COVID-19 vaccination in India. medRxiv. 2021. doi: 10.1101/2021.02.08.21251366.
    [Google Scholar]
  17. Walsh EE, Frenck Jr. RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. The New England Journal of Medicine. 2020;:383:2439–50.
    [Google Scholar]
  18. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020:(586):589–93.
    [Google Scholar]
  19. Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes & Metabolic Syndrome. 2021; 15:(5):102207.
    [Google Scholar]
  20. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. JAMA. 2020; 324:(10):951–60.
    [Google Scholar]
  21. Zhu F-C, Li Y-H, Guan X-H, Hou L-H, Wang W-J, Li J-X, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet. 2020; 395:(10240):1845–54.
    [Google Scholar]
  22. Centres for Diseases Control and Prevention. Reactions and adverse events of the Pfizer-BioNTech COVID-19 vaccine. [Internet]. CDC; 2020 [accessed July 7, 2021]. Available from: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html.
    [Google Scholar]
  23. EUA, Pfizer COVID-19 vaccine EUA fact sheet for healthcare providers administering vaccine (vaccination providers). [Internet]. EUA; 2021 [accessed June 31, 2021]. Available from: https://www.fda.gov/media/144413/download.
  24. Abbas AH, Rasheed MA, Al-Hindy HA-A, Mousa MJ, Al-Shalah HAA. The role of serum IL-1β in combination with fractional exhaled nitric oxide in the diagnosis of adult bronchial asthma. NeuroQuantology. 2021; 19:(8):13–9.
    [Google Scholar]
  25. Al-Hindy HA-AM, Al-Athari AJH, Mousa MJ, Hameed SJ, Obeed SH. The utility of serum IL-1β and CRP together with fractional exhaled nitric oxide in the diagnosis of asthma in adults. NeuroQuantology. 2021; 19:(8):119–24.
    [Google Scholar]
  26. Alkhazraji EK, Abdulla A, Alzughaibi MA, Alhindy HA-A, Mousa MJ. Positive correlation of circulating tumor necrosis factor-alpha (Tnfα) with spirometric pulmonary tests in adult asthmatic patients. Biochemical and Cellular Archives. 2021; 21:(S1):2605–10.
    [Google Scholar]
  27. Jasim AH, A.H.A., Hammoud SS, Al-Hindy HA-AM. The role of interleukin 17 cytokine in asthma and its association with severity of attack. Archivos Venezolanos de Farmacologia y Terapeutica. 2023 (In press).
    [Google Scholar]
  28. Saeed BQ, Al-Shahrabi R, Alhaj, SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. International Journal of Infectious Diseases. 2021:(21):00646-9.
    [Google Scholar]
  29. Andrzejczak-Grządko S, Czudy, Donderska M. Side effects after COVID-19 vaccinations among residents of Poland. European Review for Medical and Pharmacological Sciences. 2021; 25:(12):4418–21.
    [Google Scholar]
  30. Zhu F-C, Li Y-H, Guan X-H, Hou L-H, Wang W-J, Li J-X, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet. 2020; 395:(10240):1845–54.
    [Google Scholar]
  31. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020; 324:(10):951–60.
    [Google Scholar]
  32. CDC, Local Reactions. Systemic reactions, adverse events, and Serious adverse events: Pfizer-BioNTech COVID-19 vaccine. 2021 [cited 2021 7 July 2021]. 2021.
    [Google Scholar]
  33. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021; 397:(10269):99–111.
    [Google Scholar]
  34. Caballero ML, Quirce S. Delayed hypersensitivity reactions caused by drug excipients: a literature review. Journal of Investigational Allergology and Clinical Immunology. 2020; 30:(6):400–8.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/jemtac.2022.ismc.6
Loading
/content/journals/10.5339/jemtac.2022.ismc.6
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): adverse effectsAstraZenecaCOVID-19PfizerSinopharm and vaccine
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error